Spyre Therapeutics, Inc.
SYRE
$28.40
-$0.26-0.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 45.25M | 40.15M | 41.62M | 50.48M | 44.74M |
| Gross Profit | -45.25M | -40.15M | -41.62M | -50.48M | -44.74M |
| SG&A Expenses | 11.64M | 11.79M | 11.94M | 10.77M | 10.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.89M | 51.94M | 53.57M | 61.25M | 55.39M |
| Operating Income | -56.89M | -51.94M | -53.57M | -61.25M | -55.39M |
| Income Before Tax | -11.18M | -36.72M | -44.79M | -56.30M | -69.01M |
| Income Tax Expenses | -- | -- | -15.00K | 1.00K | 18.00K |
| Earnings from Continuing Operations | -11.18M | -36.72M | -44.77M | -56.30M | -69.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.18M | -36.72M | -44.77M | -56.30M | -69.03M |
| EBIT | -56.89M | -51.94M | -53.57M | -61.25M | -55.39M |
| EBITDA | -- | -- | -- | -61.07M | -55.21M |
| EPS Basic | -0.15 | -0.49 | -0.60 | 0.04 | -1.06 |
| Normalized Basic EPS | -0.12 | -0.48 | -0.46 | -0.64 | -0.85 |
| EPS Diluted | -0.15 | -0.49 | -0.60 | 0.04 | -1.06 |
| Normalized Diluted EPS | -0.12 | -0.48 | -0.46 | -0.64 | -0.85 |
| Average Basic Shares Outstanding | 60.41M | 60.33M | 60.27M | 55.26M | 50.89M |
| Average Diluted Shares Outstanding | 60.41M | 60.33M | 60.27M | 55.26M | 50.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |